Peter LJ Wijngaard, Ph.D., has served as a Director of our company since June 2020. Dr. Wijngaard is currently the Chief Development Officer at The Medicines Company which was acquired by Novartis in January 2020 for 9.7 Bio USD. He has more than 25 years of experience in the pharmaceutical industry working for Sandoz, Pharmacia, F. Hoffmann-La Roche, Viropharma and The Medicines Company in various roles in Product Development, Medical Affairs and Business Development. He served on the Board of Directors of Isotechnika Pharmaceuticals Inc, Aurinia Pharmaceuticals Inc and Ciclofilin Pharmaceuticals Inc. He also was a Trustee of the Roche Organ Transplant Research Foundation Board.  Dr Wijngaard has a PhD in Transplantation Immunology from Utrecht University, the Netherlands.